# Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

> **NCT00825201** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cavity Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **OTHER:** liquid chromatography
- **OTHER:** mass spectrometry
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00825201
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-01-16
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-01-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825201, "Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00825201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*